Skip to content
Press Releases

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Veracyte Announces Presentation of New Data Validating Accuracy of BRAF V600E and Parathyroid Tissue Classifiers at ATA Annual Meeting
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)-- Veracyte, Inc. (NASDAQ: VCYT) announced that data presented at the 87 th Annual Meeting of the American Thyroid Association (ATA) being held October 18-22 in Victoria, BC , Canada demonstrate the accuracy of identification of BRAF V600E and
View HTML
Toggle Summary Veracyte Announces New Data Demonstrating Clinical Utility of Percepta Bronchial Genomic Classifier to be Presented at CHEST Annual Meeting 2017
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)-- Veracyte, Inc. (NASDAQ:VCYT) today announced that data from a prospective clinical utility study demonstrating the ability of the Percepta ® Bronchial Genomic Classifier to safely reduce unnecessary invasive procedures in lung cancer screening and
View HTML
Toggle Summary Veracyte Chairman and CEO Bonnie Anderson Receives Prestigious Innovation Award at Biomedical Engineering Society Annual Meeting
- The Coulter Foundation's Wallace H. Coulter Award for Healthcare Innovation Recognizes Excellence and Leadership in Clinical Diagnostic Medicine - SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)-- Veracyte, Inc . (NASDAQ: VCYT) announced today that the company's Chairman and CEO Bonnie Anderson is
View HTML
Toggle Summary Veracyte Announces Data From Five Studies Validating the Next-Generation Afirma Genomic Sequencing Classifier to Be Presented at ATA 2017 Annual Meeting
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)-- Veracyte, Inc. (NASDAQ: VCYT) today announced that data from five studies validating the performance of the next-generation Afirma ® Genomic Sequencing Classifier (GSC) in thyroid cancer diagnosis will be presented at the 87 th Annual Meeting of the
View HTML
Toggle Summary Veracyte Announces Release of 2018 Preliminary Reimbursement Rate for Afirma Genomic Classifier Under PAMA
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)-- Veracyte, Inc . (NASDAQ: VCYT) today announced that the Centers for Medicare & Medicaid Services (CMS) published preliminary 2018 rates for clinical diagnostic laboratory tests. The reimbursement rate for the Afirma Genomic Classifier (code 81545) is
View HTML
Toggle Summary Awareness Campaign Takes Lung Cancer Risk Head-On, Asking North Carolinians To Screen Together
Veracyte, Inc. and the Lung Cancer Initiative Partner to Launch New Pilot Campaign in North Carolina
View HTML
Toggle Summary Veracyte Launches Campaign to Save Lives through Early Screening for Lung Cancer
- Screen Together Campaign with Lung Cancer Initiative Underscores Company's Commitment to Improving Outcomes for People at High Risk of Lung Cancer - SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)-- Veracyte, Inc . (NASDAQ: VCYT) today announced that it has partnered with the Lung Cancer Initiative
View HTML
Toggle Summary Veracyte to Present at the Cantor Fitzgerald Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)-- Veracyte, Inc. (NASDAQ: VCYT) today announced that Bonnie H. Anderson , chairman and chief executive officer, will present at the Cantor Fitzgerald Global Healthcare Conference on Tuesday, September 26, 2017 at 2:15 p.m. Eastern Time in New York, NY .
View HTML
Toggle Summary Veracyte to Present at the Morgan Stanley 15th Annual Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)-- Veracyte, Inc. (NASDAQ: VCYT) today announced that Bonnie H. Anderson , chairman and chief executive officer, will present at the Morgan Stanley 15th Annual Global Healthcare Conference on Monday, September 11, 2017 at 5:25 p.m.
View HTML
Toggle Summary Veracyte Announces Second Quarter 2017 Financial Results
Reports 25% Revenue Growth, to $18.4 Million , and 37% Improvement in Loss from Operations Over Prior Year Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)-- Veracyte, Inc. (NASDAQ: VCYT) today announced financial results for the second quarter ended
View HTML